Should I buy or sell Evaxion Biotech A/S stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVAX shares. View EVAX analyst ratings or view top-rated stocks .

What is Evaxion Biotech A/S's stock price target for 2024?

1 Wall Street research analysts have issued 1-year price targets for Evaxion Biotech A/S's shares. Their EVAX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,172.7% from the stock's current price. View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts .

How have EVAX shares performed in 2023?

Evaxion Biotech A/S's stock was trading at $1.7750 on January 1st, 2023. Since then, EVAX shares have decreased by 69.0% and is now trading at $0.55. View the best growth stocks for 2023 here .

Are investors shorting Evaxion Biotech A/S?

Evaxion Biotech A/S saw a decrease in short interest in November. As of November 15th, there was short interest totaling 217,400 shares, a decrease of 22.8% from the October 31st total of 281,600 shares. Based on an average trading volume of 140,900 shares, the days-to-cover ratio is presently 1.5 days. View Evaxion Biotech A/S's Short Interest .

When is Evaxion Biotech A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 11th 2023. View our EVAX earnings forecast .

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings data on Tuesday, August, 22nd. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01.

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Who are Evaxion Biotech A/S's major shareholders?

Evaxion Biotech A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include AE Wealth Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Evaxion Biotech A/S Stock Price, News & Analysis (NASDAQ:EVAX)

$0.61

-0.21 (-25.60%)

(As of 03:46 PM ET)

Compare

Today's Range: $0.55
▼
$0.77
50-Day Range: $0.68
▼
$1.17
52-Week Range: $0.47
▼
$2.44

Volume: 751,997 shs
Average Volume: 275,072 shs
Market Capitalization: $17.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Evaxion Biotech A/S MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,172.7% Upside
$7.00 Price Target
Short Interest: Healthy
0.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.05
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

299th out of 949 stocks

Biological Products, Except Diagnostic Industry

48th out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Evaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Evaxion Biotech A/S has a forecasted upside of 1,172.7% from its current price of $0.55.
Amount of Analyst Coverage
Evaxion Biotech A/S has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.78% of the outstanding shares of Evaxion Biotech A/S have been sold short.
Short Interest Ratio / Days to Cover
Evaxion Biotech A/S has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Evaxion Biotech A/S has recently decreased by 22.80%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Evaxion Biotech A/S does not currently pay a dividend.
Dividend Growth
Evaxion Biotech A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EVAX.

3.4

News and Social Media Coverage

News Sentiment
Evaxion Biotech A/S has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Evaxion Biotech A/S this week, compared to 1 article on an average week.
Search Interest
2 people have searched for EVAX on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.58% of the stock of Evaxion Biotech A/S is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Evaxion Biotech A/S is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evaxion Biotech A/S is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evaxion Biotech A/S has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Evaxion Biotech A/S Stock (NASDAQ:EVAX)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

EVAX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVAX Stock News Headlines

December 3, 2023 | americanbankingnews.com

Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Declines By 22.8%

November 28, 2023 | finance.yahoo.com

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 15, 2023 | finance.yahoo.com

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy

November 9, 2023 | morningstar.com

ADRs End Lower; Evaxion Biotech A/S Declines 30%

November 6, 2023 | finance.yahoo.com

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

October 31, 2023 | morningstar.com

ADRs Hold Steady; Fresh2 Group Climbs 23%

October 31, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 31, 2023 | finance.yahoo.com

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

October 26, 2023 | finanznachrichten.de

Evaxion Biotech: New and Exciting Clinical Data on Evaxion's AI-Immunology-Based Personalized Cancer Vaccines to be Presented

October 26, 2023 | tmcnet.com

New and Exciting Clinical Data on Evaxion's AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

October 26, 2023 | finance.yahoo.com

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

October 5, 2023 | finance.yahoo.com

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

September 21, 2023 | finance.yahoo.com

Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab

September 20, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

September 20, 2023 | finance.yahoo.com

Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

September 18, 2023 | finance.yahoo.com

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

August 30, 2023 | bloomberg.com

Novo Buys Embark Biotech to Find New Avenues for Weight Loss

August 29, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion announces Executive Management Changes to strengthen the AI-strategy

August 29, 2023 | finance.yahoo.com

Evaxion announces Executive Management Changes to strengthen the AI-strategy

August 24, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Rising, Backed by Mostly Firmer Markets

August 23, 2023 | finance.yahoo.com

Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript

August 23, 2023 | finance.yahoo.com

Q2 2023 Evaxion Biotech A/S Earnings Call

August 18, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion Announces Business Update and Second Quarter 2023 Financial Results

August 18, 2023 | finance.yahoo.com

Evaxion Announces Business Update and Second Quarter 2023 Financial Results

August 3, 2023 | msn.com

Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst

See More Headlines

Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/22/2023
Today: 12/05/2023
Next Earnings (Estimated): 12/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EVAX
CUSIP: N/A
CIK: 1828253
Web: www.evaxion-biotech.com
Phone: 45-5353-1850
Fax: N/A
Employees: 63
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +902.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -452.78%
Return on Assets: -126.54%

Debt

Debt-to-Equity Ratio: 3.95
Current Ratio: 2.81
Quick Ratio: 2.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.35 per share
Price / Book: 2.00

Miscellaneous

Outstanding Shares: 27,919,000
Free Float: 16,294,000
Market Cap: $19.50 million
Optionable: Not Optionable
Beta: 0.08

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Niels Iversen Moller M.D. (Age 44)
Co-Founder, VP of Business & Director
Comp: $120k
Mr. Andreas Holm Mattsson (Age 47)
Co-Founder and Chief AI & Culture Officer
Comp: $319k
Mr. Jesper Nyegaard Nissen (Age 53)
CFO & COO
Comp: $346.97k
Dr. Birgitte Rono Ph.D. (Age 47)
Chief Scientific Officer
Comp: $336k
Mr. Christian Kanstrup (Age 51)
Chief Executive Officer
Dr. Jürgen Langhärig EMBA
Ph.D., Head of Business Development & Member of Advisory Board

Key Competitors

View All Competitors

Institutional Ownership

AE Wealth Management LLC
Bought 48,633 shares on 10/11/2023
Ownership: 0.176%

View All Institutional Transactions

EVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVAX shares.
View EVAX analyst ratings or view top-rated stocks.
What is Evaxion Biotech A/S's stock price target for 2024?: 1 Wall Street research analysts have issued 1-year price targets for Evaxion Biotech A/S's shares. Their EVAX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,172.7% from the stock's current price.
View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts.
How have EVAX shares performed in 2023?: Evaxion Biotech A/S's stock was trading at $1.7750 on January 1st, 2023. Since then, EVAX shares have decreased by 69.0% and is now trading at $0.55.
View the best growth stocks for 2023 here.
Are investors shorting Evaxion Biotech A/S?: Evaxion Biotech A/S saw a decrease in short interest in November. As of November 15th, there was short interest totaling 217,400 shares, a decrease of 22.8% from the October 31st total of 281,600 shares. Based on an average trading volume of 140,900 shares, the days-to-cover ratio is presently 1.5 days.
View Evaxion Biotech A/S's Short Interest.
When is Evaxion Biotech A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, December 11th 2023.
View our EVAX earnings forecast.

How were Evaxion Biotech A/S's earnings last quarter?: Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings data on Tuesday, August, 22nd. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01.
When did Evaxion Biotech A/S IPO?: (EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.
Who are Evaxion Biotech A/S's major shareholders?: Evaxion Biotech A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include AE Wealth Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Evaxion Biotech A/S?: Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EVAX) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial